Ospedale Regionale di Bellinzona e Vali

The trials here

What the 2 trials at this site are about, from their registry records.

Conditions

• Lung cancer2 trials

Phase

• Phase 32 trials

Status

• Active, not recruiting2 trials

Lead sponsor

• Amgen2 trials

Running trials

• Active, not recruiting

  Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

  NCT06211036· Phase 3· Amgen· Source

• Active, not recruiting

  Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

  NCT06117774· Phase 3· Amgen· Source